首页> 外文期刊>American Journal of Kidney Diseases: The official journal of the National Kidney Foundation >Successful peritoneal dialysis after renal transcatheter arterial embolization in autosomal dominant polycystic kidney disease.
【24h】

Successful peritoneal dialysis after renal transcatheter arterial embolization in autosomal dominant polycystic kidney disease.

机译:肾经导管动脉栓塞术后常染色体显性多囊肾疾病成功进行腹膜透析。

获取原文
获取原文并翻译 | 示例
           

摘要

When continuous ambulatory peritoneal dialysis (CAPD) is performed in patients with autosomal dominant polycystic kidney disease (ADPKD), various complications specific to ADPKD, such as abdominal hernias, leakage of dialysate from the peritoneal cavity, and enlargement of the kidneys or liver, need to be considered. We encountered a patient with ADPKD who had severe nephromegaly and abdominal swelling that progressed even after starting CAPD. To treat enlarged kidneys in patients with ADPKD, renal transcatheter arterial embolization (TAE) is a therapeutic option. We report the outcome of TAE in our CAPD patient, a 63-year-old Japanese woman who was admitted to our hospital to treat enlarged kidneys 4 years after starting CAPD for end-stage renal disease secondary to ADPKD. Residual kidney function was minimal. TAE was performed for both kidneys using platinum microcoils under epidural anesthesia. Six months after TAE, volumes of the left and right kidneys had decreased from 3,037 to 1,440 cm~3 and 5,251 to 1,884 cm~3, respectively, and the patient's abdominal distension (with umbilical and inguinal hernias) subsided (Fig 1). Peritoneal dialysis (PD) fluid volume could be increased from 1,200 to 1,600 mL. Weekly Kt/V increased from 1.38 to 1.76, and total creatinine clearance increased from 27.8 to 44.4 L/wk when using 1,600 mL of PD fluid (Fig 1). Prolongation of the duration of PD was achieved. We conclude that renal TAE is a therapeutic option for patients with ADPKD for whom PD fluid volume is limited by nephromegaly.
机译:在常染色体显性遗传性多囊肾病(ADPKD)患者中进行不卧床腹膜透析(CAPD)时,ADPKD特有的各种并发症,例如腹疝,腹膜透析液渗漏以及肾脏或肝脏肿大被考虑。我们遇到了ADPKD患者,即使开始CAPD后也有严重的肾肿大和腹部肿胀。为了治疗ADPKD患者的肾脏增大,肾导管动脉栓塞术(TAE)是一种治疗选择。我们报告了CAPD患者的TAE结局,该患者是一名63岁的日本女性,在因继发于ADPKD的终末期肾脏疾病而开始CAPD的4年后入院治疗肾脏扩大。残余肾功能微乎其微。使用硬膜外麻醉下的铂微线圈对两个肾脏进行TAE。 TAE后六个月,左肾和右肾的体积分别从3,037减少至1,440 cm〜3,从5,251减少至1,884 cm〜3,并且患者的腹胀(脐带和腹股沟疝)消退(图1)。腹膜透析(PD)的液体量可以从1,200 mL增加到1,600 mL。当使用1,600 mL PD液体时,每周Kt / V从1.38增加到1.76,总肌酐清除率从27.8增加到44.4 L / wk(图1)。 PD的持续时间得以延长。我们得出的结论是,对于PD液量受肾肿大限制的ADPKD患者,肾脏TAE是一种治疗选择。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号